MariTide remains investigational as of October 12, 2026 and is not FDA-approved for routine treatment. Manufacturer news and study enrollment are separate from FDA approval and pharmacy availability.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
MariTide, or maridebart cafraglutide, combines GIP-receptor antagonism and GLP-1 agonist activity. Longer dosing intervals are being studied.
MariTide remains investigational as of October 12, 2026 and is not FDA-approved for routine treatment. Manufacturer news and study enrollment are separate from FDA approval and pharmacy availability.
Trial eligibility is determined by the specific protocol and study team. A person may still be evaluated for currently approved diabetes or weight-management care. Study participation is not guaranteed and must not require stopping prescribed treatment without a plan.
Check the manufacturer’s current development update and an official ClinicalTrials.gov record. Confirm the recruiting site through the listed study contact, eligibility, consent process, and follow-up obligations. For care now, discuss approved options and their risks with a clinician. Study of monthly or less frequent schedules does not mean a monthly or quarterly injection can be booked.
Bring your diagnosis, weight and medicine history, relevant tests, and the exact trial record if you want to discuss research participation. Confirm trial status and location directly with the study team.
Do not buy research-use peptides or recreate combinations yourself. Product identity, concentration, quality, and safety may be uncertain. Contact the study team listed in the official trial record to discuss research access.
A legitimate study uses its protocol, monitoring, and adverse-event contact process. Routine clinical care and refills remain important while you consider research. New trial results do not establish safety or benefit for an individual.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
No. An announcement can report study results, enrollment, or an application. Each is separate from FDA approval, a pharmacy launch, insurance coverage, and a Nao Medical service. MariTide remains investigational as of October 12, 2026 and is not FDA-approved for routine treatment. Manufacturer news and study enrollment are separate from FDA approval and pharmacy availability.
Trial enrollment is handled by the recruiting study team. Ask the recruiting study team through the official trial record about eligibility and location. A routine clinical appointment does not guarantee enrollment. Continue prescribed care while discussing trial participation.
MariTide remains investigational as of October 12, 2026. Monthly or less frequent intervals are development questions, not an approved schedule available for booking. Discuss approved care now and confirm any trial with its study team.
Use an official ClinicalTrials.gov record and the manufacturer’s trial information. Check the study’s current recruitment status, location, eligibility, contact details, and consent process directly with the listed study team. A promotional post or an online product listing is not a trial enrollment route.
MariTide is Amgen’s investigational medicine maridebart cafraglutide, formerly called AMG 133. It combines blockade of the GIP receptor with activation of the GLP-1 pathway. Amgen is studying it for obesity and related conditions in the Phase 3 MARITIME program. Longer dosing intervals are research questions, not an approved monthly or quarterly injection service.
As of October 9, 2026, MariTide remains investigational in Amgen’s Phase 3 program. It is not available as an FDA-approved routine treatment, and a pharmacy launch date has not been confirmed. A study readout or company forecast does not establish when you can receive it. Ask about approved care now, or check an official recruiting trial with its study team.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
